00:03Positive signs regarding waiting lists in healthcare. Health Minister Orazio
00:09Schillace, on the sidelines of an event in Rome, commented on the data from the Agenas bulletin and
00:14claimed the path started by the Government with the reform dedicated to reducing the time for
00:20visits and tests. Regarding waiting lists, I believe that the path taken two years ago with the law is
00:26the right one, he said we have established healthy competition between the regions. The Minister has
00:32stressed that he did not want to distinguish between the results obtained by the public health service and those
00:38of the accredited private sector. The objective, he underlined, is to guarantee citizens services within the timeframe
00:44expected, regardless of who provides them. However, the issue of territorial differences remains. According to
00:52Schillaci, the inequalities between regions in healthcare provision and care
00:57of patients still represent the main criticality. Signs of improvement on the front
01:05waiting lists, but the problem is far from solved. This is what emerges from the first bulletin
01:11Agenas periodical that analyses the first half of 2026. Compared to the same period last year
01:18year, over 1,600,000 more specialist visits and diagnostic tests were carried out
01:25within the maximum guaranteed timeframe. Reservations increased by 12%, reaching almost 15
01:32millions and the share of services provided within the expected timeframe is also growing, especially for
01:38Urgent and short-term priority cases. Despite the progress, nearly 2,800,000 procedures remain.
01:46carried out beyond the established limits, a fact which confirms that the increase in supply does not
01:52is still sufficient to reduce waiting lists. The report also highlights strong
01:57differences between regions. Lombardy and Liguria are among those that have improved the most, while
02:03critical issues persist in other areas of the country, both in terms of delivery times and in the attribution
02:09of priority classes. It remains on standby at the Business Committee
02:15The House of Representatives approved the bill on healthcare professions. The measure does not
02:20there is still a date for the resumption of the parliamentary examination, while the issues still remain open
02:25Several political and technical issues remain. Among the most controversial points is the amendment on reinstatement.
02:31of doctors who had not been vaccinated against Covid-19. The measure, from what we understand,
02:37It would continue to divide the majority and still has technical aspects to be defined.
02:42The text of the bill has already been reformulated and may undergo further changes.
02:47before returning to the Commission for examination. Among the still open questions is also
02:52the rule on the exclusivity of the relationship for doctors of the National Health Service.
02:58The Presidency Office of the Social Affairs Commission is expected in the next few hours, called
03:03to take stock of the work schedule. For now, however, the future of the project
03:08of law remains tied to the search for an agreement on the most sensitive issues, starting from the
03:14reinstatement of anti-vax doctors.
03:18New criticisms of the draft decree on the tariffs of outpatient specialist care and
03:23of prosthetic care. The National Union of Outpatient Clinics, Polyclinics, and Hospital Dentists
03:29of Private individuals, the UAP, claims that the text does not resolve the critical issues of the previous provision
03:35annulled by the Lazio Regional Administrative Court. According to the association, most tariffs remain unchanged.
03:42Of over 2,000 performances analyzed, nearly 1,600 show no increase. For the
03:48President Maria Stella Giorlandino, the planned adjustments would not be sufficient to cover
03:53costs incurred by the facilities for personnel, technology, equipment, and energy. The UAP
04:00He also contests the lack of prior consultation with trade organizations
04:05and asks the Ministry of Economy to verify the coherence between the allocated resources and the tariffs
04:11proposals.
04:13Italy completes first year of full implementation of new European regulation on clinical trials
04:20clinics without losing ground. This is what emerges from the 22nd AIFA report. In 2024,
04:27669 studies were authorized, a figure substantially stable compared to the previous year. To change
04:36However, it is the composition of the research. International experiments are growing and they represent
04:41over 90% of the total and the studies promoted by the pharmaceutical industry are increasing, while
04:48academic research, national studies and studies dedicated to diseases are declining
04:53rare. Oncology remains the leading research sector, with 248 trials
04:59authorized and the largest increase compared to 2023. However, studies on
05:05Nervous system diseases. According to AIFA, the new regulatory framework favors research
05:12profit, but it puts the non-profit sector in difficulty, especially due to the greater complexity
05:18of administrative procedures.
